Serum and sputum levels of cefaclor
- PMID: 548940
Serum and sputum levels of cefaclor
Abstract
In a cross-over study, 10 healthy adult volunteers received 1 g cefaclor and 1 g cephalexin orally 1 hour after a standard breakfast. Serum levels of cefaclor rose somewhat faster and were higher than those of cephalexin in the first 60 minutes. At the end of the second hour the serum concentration of cephalexin was 50--100% higher. The area under the serum level curve averaged 45 hr-micrograms/ml for cefaclor and 60 hr-micrograms/ml for cephalexin. Calculated pharmacokinetic constants indicate that the absorption rate of cefaclor was nearly the same as that of cephalexin. The serum half-life of cefaclor was 1 hr. The urine recovery of cefaclor for 9 hours averaged 65%, whereas cephalexin resulted in a urine recovery of 85%. To evaluate sputum levels, 15 adult patients with bronchial carcinoma and secondary bronchitis or pneumonia were treated with 0.5 g of cefaclor orally 4 times daily. The mean individual sputum levels were 0.44 micrograms/ml (after the first dose) and 0.54 micrograms/ml (after repeated administration). In 10 other patients, after a single 1 g dose of cefaclor mean sputum levels after 1 hour and 3 hours doubled, whereas peak concentrations in sputum after 2 hours did not differ significantly. These results suggest that cefaclor will be useful in respiratory tract infections caused by sensitive bacteria.
Similar articles
-
[Comparative pharmacokinetics of oral cephalosporins: cephalexin, cefaclor and cefadroxil (author's transl)].Arzneimittelforschung. 1980;30(3):505-9. Arzneimittelforschung. 1980. PMID: 7387765 Clinical Trial. German.
-
In vitro activity and pharmacokinetics of cefaclor in normal volunteers and patients with renal failure.Postgrad Med J. 1979;55 Suppl 4:12-6. Postgrad Med J. 1979. PMID: 548939
-
Treatment of acute bronchitis and pneumonia with cefaclor.Postgrad Med J. 1979;55 Suppl 4:59-61. Postgrad Med J. 1979. PMID: 398482 Clinical Trial.
-
Evaluation of cefaclor.Am J Hosp Pharm. 1981 Jan;38(1):54-8. Am J Hosp Pharm. 1981. PMID: 7011003 Review.
-
Pharmacokinetic profile of cefaclor.Int J Clin Pharmacol Ther. 1997 Sep;35(9):374-80. Int J Clin Pharmacol Ther. 1997. PMID: 9314090 Review.
Cited by
-
Branhamella catarrhalis respiratory infections in The Netherlands.Drugs. 1986;31 Suppl 3:83-6. doi: 10.2165/00003495-198600313-00018. Drugs. 1986. PMID: 3732084
-
[Experience with cefaclor in the treatment of ear, nose and throat infections. Indications for cefaclor therapy (author's transl)].Infection. 1979;7 Suppl 6:609-14. doi: 10.1007/BF01659748. Infection. 1979. PMID: 551089 German.
-
Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice.Infection. 1995;23 Suppl 1:S15-20. doi: 10.1007/BF02464954. Infection. 1995. PMID: 7782110 Clinical Trial.
-
Evaluation of the penetration of ciprofloxacin and amoxycillin into the bronchial mucosa.Thorax. 1988 Sep;43(9):715-9. doi: 10.1136/thx.43.9.715. Thorax. 1988. PMID: 3194878 Free PMC article.
-
[Assay of cefaclor in serum and urine (including stability test) using high pressure liquid chromatography (author's transl)].Infection. 1979;7 Suppl 6:603-5. doi: 10.1007/BF01659746. Infection. 1979. PMID: 551087 German.